NanoViricides, Inc. (NNVC.PK) Announces That DengueCide Has Received Orphan Drug Designation From the FDA
8/12/2013 10:46:27 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that DengueCide™, its drug candidate for the treatment of dengue and dengue hemorrhagic fever, has been officially designated as an orphan drug by the US FDA. This orphan drug designation qualifies NanoViricides for certain tax credits and marketing incentives under the Orphan Drug Act. In addition, the Company will qualify for the waiver of certain FDA fees when it files the New Drug Application (NDA) for DengueCide with the FDA. Further, the Company will also be eligible for a “Priority Review Voucher” (PRV) from the US FDA when the Company files a NDA for DengueCide.
Help employers find you! Check out all the jobs and post your resume.
comments powered by